AQR Capital Management LLC Raises Stock Holdings in Inogen, Inc. (NASDAQ:INGN)

AQR Capital Management LLC boosted its position in shares of Inogen, Inc. (NASDAQ:INGN) by 29.3% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 570,994 shares of the medical technology company’s stock after buying an additional 129,307 shares during the quarter. AQR Capital Management LLC owned approximately 2.42% of Inogen worth $4,642,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in INGN. PNC Financial Services Group Inc. grew its stake in shares of Inogen by 2,918.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,908 shares of the medical technology company’s stock worth $43,000 after purchasing an additional 7,646 shares during the last quarter. Quadrature Capital Ltd grew its holdings in shares of Inogen by 106.4% during the 4th quarter. Quadrature Capital Ltd now owns 31,071 shares of the medical technology company’s stock worth $171,000 after acquiring an additional 16,017 shares during the period. Kingswood Wealth Advisors LLC purchased a new stake in Inogen in the first quarter worth $123,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Inogen during the 1st quarter valued at $129,000. Finally, Stokes Family Office LLC purchased a new stake in shares of Inogen in the 1st quarter worth about $351,000. Institutional investors own 89.94% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Needham & Company LLC restated a “hold” rating on shares of Inogen in a report on Wednesday, August 7th. StockNews.com raised Inogen from a “sell” rating to a “hold” rating in a research report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $7.00.

Inogen Stock Performance

Shares of INGN stock opened at $9.12 on Friday. The company has a market capitalization of $215.02 million, a price-to-earnings ratio of -2.20 and a beta of 1.04. Inogen, Inc. has a one year low of $4.13 and a one year high of $13.33. The company’s 50-day moving average is $11.02 and its 200 day moving average is $9.05.

Inogen (NASDAQ:INGN) last posted its quarterly earnings results on Tuesday, August 6th. The medical technology company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.31. Inogen had a negative net margin of 28.30% and a negative return on equity of 45.37%. The firm had revenue of $88.77 million for the quarter, compared to analysts’ expectations of $82.50 million. During the same quarter in the prior year, the company posted ($0.42) earnings per share. The business’s revenue for the quarter was up 6.1% on a year-over-year basis. As a group, research analysts predict that Inogen, Inc. will post -1.92 earnings per share for the current fiscal year.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.